{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:34:44Z","timestamp":1780338884930,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cellimm.2024.104914","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:51:37Z","timestamp":1735631497000},"page":"104914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The effect of tocilizumab treatment for skin fibrosis by inhibiting CD38+ macrophages in systemic sclerosis"],"prefix":"10.1016","volume":"408","author":[{"given":"Hongzhen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2024.104914_bb0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00296-017-3916-x","article-title":"Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group","volume":"38","author":"S\u00e1nchez-Cano","year":"2018","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cellimm.2024.104914_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","article-title":"Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire","volume":"81","author":"Becker","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cellimm.2024.104914_bb0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.14162","article-title":"Diagnostic criteria, severity classification and guidelines of systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0020","first-page":"e175","article-title":"Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study, the lancet","volume":"3","author":"Dobrota","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.cellimm.2024.104914_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010587","article-title":"Amyotrophic lateral sclerosis Pathoetiology and pathophysiology: roles of astrocytes, gut microbiome, and muscle interactions via the mitochondrial Melatonergic pathway, with disruption by glyphosate-based herbicides","volume":"24","author":"Anderson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellimm.2024.104914_bb0030","first-page":"1202","article-title":"Macrophage infiltration in the skin of patients with systemic sclerosis","volume":"19","author":"Ishikawa","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate Mofetil and Oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.cellimm.2024.104914_bb0040","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/acr.24724","article-title":"Prognostic value of cardiac Axis deviation in systemic sclerosis-related pulmonary hypertension","volume":"74","author":"Lui","year":"2022","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.cellimm.2024.104914_bb0045","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.cellimm.2024.104914_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124205","article-title":"Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review","volume":"10","author":"Omair","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2024.104914_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313127","article-title":"Current status of biomarkers in anti-N-methyl-D-aspartate receptor encephalitis","volume":"22","author":"Ciano-Petersen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2021","key":"10.1016\/j.cellimm.2024.104914_bb0060","first-page":"1","article-title":"Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis","volume":"2","author":"Tian","year":"2018","journal-title":"Rheumatol. Immunol. Res."},{"key":"10.1016\/j.cellimm.2024.104914_bb0065","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2024.104914_bb0070","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cellimm.2024.104914_bb0075","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3346\/jkms.2010.25.9.1364","article-title":"A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"25","author":"Higuchi","year":"2010","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.cellimm.2024.104914_bb0080","first-page":"963","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial, the lancet","volume":"8","author":"Khanna","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.cellimm.2024.104914_bb0085","series-title":"Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease, Arthritis & Rheumatology (Hoboken, N.J.)","first-page":"1301","volume":"vol. 73","author":"Roofeh","year":"2021"},{"key":"10.1016\/j.cellimm.2024.104914_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00296-020-04732-z","article-title":"Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single Centre pilot study","volume":"41","author":"Adrovic","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cellimm.2024.104914_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152376","article-title":"Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: a post hoc analysis from the focuSSced trial","volume":"65","author":"Bernstein","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cellimm.2024.104914_bb0100","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cellimm.2024.104914_bb0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.joca.2018.10.010","article-title":"IL6 receptor blockade preserves articular cartilage and increases bone volume following ischemic osteonecrosis in immature mice","volume":"27","author":"Kamiya","year":"2019","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.cellimm.2024.104914_bb0110","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cellimm.2024.104914_bb0115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1600-0625.2008.00828.x","article-title":"Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma","volume":"18","author":"Higashi-Kuwata","year":"2009","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6630295","article-title":"CD38 and regulation of the immune response cells in Cancer","volume":"2021","author":"Dwivedi","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cellsig.2018.02.006","article-title":"Identification of macrophage-related candidate genes in lupus nephritis using bioinformatics analysis","volume":"46","author":"Shu","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellimm.2024.104914_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/QAI.0000000000001480","article-title":"Brief report: peripheral monocyte\/macrophage phenotypes associated with the evolution of cognitive performance in HIV-infected patients","volume":"76","author":"Fabbiani","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.cellimm.2024.104914_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112794","article-title":"Punicalagin prevents inflammation in LPS-induced RAW264.7 macrophages by inhibiting FoxO3a\/autophagy signaling pathway","volume":"11","author":"Cao","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.cellimm.2024.104914_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2016.01.020","article-title":"Caffeine prevents LPS-induced inflammatory responses in RAW264.7 cells and zebrafish","volume":"248","author":"Hwang","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cellimm.2024.104914_bb0150","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa198","article-title":"Antifibrogenic activities of CYP11A1-derived vitamin D3-hydroxyderivatives are dependent on RORgamma","volume":"162","author":"Janjetovic","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.cellimm.2024.104914_bb0155","doi-asserted-by":"crossref","first-page":"E298","DOI":"10.1210\/jc.2012-3074","article-title":"20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo","volume":"98","author":"Slominski","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cellimm.2024.104914_bb0160","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.jid.2024.04.022","article-title":"Biological effects of CYP11A1-derived vitamin D and Lumisterol metabolites in the skin","volume":"144","author":"Slominski","year":"2024","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0165","first-page":"321","article-title":"[recent research on cytokines associated with anti-N-methyl-D-aspartate receptor encephalitis], Zhongguo dang dai er ke za zhi =","volume":"25","author":"Zheng","year":"2023","journal-title":"Chinese J. Contemporary Pediatr."},{"key":"10.1016\/j.cellimm.2024.104914_bb0170","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/14397595.2013.874749","article-title":"Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab","volume":"25","author":"Shima","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/rheumatology\/kex396","article-title":"Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis","volume":"57","author":"Arnold","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cellimm.2024.104914_bb0180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yjmcc.2022.01.008","article-title":"Benefits in cardiac function by CD38 suppression: improvement in NAD(+) levels, exercise capacity, heart rate variability and protection against catecholamine-induced ventricular arrhythmias","volume":"166","author":"Agorrody","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.cellimm.2024.104914_bb0185","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI4304","article-title":"Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A","volume":"103","author":"Kawaguchi","year":"1999","journal-title":"J. Clin. Invest."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874924001175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874924001175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T18:37:10Z","timestamp":1740335830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874924001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"alternative-id":["S0008874924001175"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104914","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of tocilizumab treatment for skin fibrosis by inhibiting CD38+ macrophages in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104914"}}